Antisecretory Agents
Pathophysiology Of Secretory Diarrhea
Mechanism Of Ion Imbalance
- Active electrolyte and water fluxes directed toward intestinal lumen.
- Characterized by inhibition of neutral sodium-chloride absorption within villous enterocytes.
- Exaggerated electrogenic chloride secretion originates from secretory crypt cells.
- Chloride secretion mediated by cystic fibrosis transmembrane regulator (CFTR) channels.
- Bacterial enterotoxins elevate intracellular cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), or calcium.
- Elevated secondary messengers open cellular chloride channels, precipitating massive water secretion.
- Results in large stool volumes persisting during fasting state.
- Antisecretory agents directly counteract ion secretion pathways, mitigating fluid loss.
Specific Antisecretory Agents
Racecadotril
Pharmacodynamics
- Antisecretory drug functioning as intestinal enkephalinase inhibitor.
- Reduces degradation of endogenous enkephalins within intestinal villi.
- Inhibits cAMP generation, yielding profound antisecretory effect.
Clinical Efficacy
- Administered as adjunct therapy to oral rehydration solution (ORS).
- Reduces stool output, limits diarrhea duration compared to placebo.
- Significantly lowers intravenous rehydration requirements.
- Decreases overall rehydration failure risk.
- Systematic reviews note limited overall benefit for significantly altering length of hospital stay.
- Successfully utilized in specific congenital enteropathies, including microvillus inclusion disease failing other therapies.
Adverse Profile
- Headache.
- Vomiting.
- Constipation.
Octreotide
Pharmacodynamics And Indications
- Somatostatin analog.
- Inhibits fluid secretion in severe, refractory conditions.
- Indicated for diarrhea caused by neuroendocrine tumors (NETs).
- Effective in microvillus inclusion disease.
- Useful in enterotoxin-induced severe diarrhea.
Administration And Adverse Effects
- Subcutaneous administration (0.5 to 1 mcg/kg once daily).
- May cause bradycardia.
- May induce hypoglycemia.
Loperamide
Pharmacodynamics
- Exhibits dual antimotility and antisecretory properties.
Clinical Applications
- Reduces stool numbers in older children featuring watery diarrhea.
- Improves outcomes in travelerβs diarrhea when combined with antibiotics.
Contraindications
- Febrile or toxic patients.
- Dysentery or bloody diarrhea.
- Children younger than 6 years.
Diosmectite
Pharmacodynamics And Efficacy
- Absorbent agent demonstrating antisecretory-like benefits.
- Reduces diarrhea duration during acute infectious episodes.
Summary Of Antisecretory Management
| Agent | Drug Class | Target Mechanism | Primary Indications | Adverse Profiles |
|---|---|---|---|---|
| Racecadotril | Enkephalinase inhibitor | Inhibits cAMP, blocks enkephalin degradation | Acute diarrhea, microvillus inclusion disease | Headache, vomiting, constipation |
| Octreotide | Somatostatin analog | Broad secretory inhibition | Neuroendocrine tumors, severe enterotoxin diarrhea | Bradycardia, hypoglycemia |
| Loperamide | Antimotility/Antisecretory | Motility reduction, secretory inhibition | Traveler's diarrhea, older children with watery diarrhea | Ileus risk |
| Diosmectite | Absorbent | Intestinal absorption | Infectious diarrhea | Minimal |